

Welcome to OHDSI 2022: Where should we go and how should we get there



OHDSI's mission

To improve health by empowering a community to collaboratively generate the evidence that promotes better health decisions and better care





OHDSI community We're all in this journey together...

OHDSI Collaborators

• 2,367 collaborators

- 74 countries
- 21 time zones
- 6 continents

OHDSI Data Network

- 331 data sources
 - 284 EHRs
 - 28 administrative claims
- 34 countries
- 810 million unique patient records



12 OHDSI Highlights In 2021

- #OHDSI2021 Global Symposium
- Vaccine Surveillance Methods Research
- Reproducibility Challenge
- HADES/Community Unit-Test-A-Thon
- CDM v5.4 Release
- EHDEN Progress (143 Data Partners, 47 SMEs)
- "Our Journey" Publication
- Pioneer Prostate Cancer Study-A-Thon
- The LEGEND Initiative
- The Asia-Pacific (APAC) Symposium
- Work on Adverse Events of Special Interest Around Vaccines
- Titan Awards







Incidence rate per 100 000 person years (95% prediction interval)												
lutcomer by rev	1.5 searce	6.17.00.07	19-74 wears	25.54 upper	55.64 warrs	65-74 unter	75.84 water	305 years				
ion-basmorrhatic stroke	(Sycars	onyours	10-04 years	55549005	55 61 9 64 5	op stage as	Joorgans	cospens				
iemale	104.0	4134-339	10/4 - 94	82/111-412	227/22 4+ 1002	433 (7714-33766)	STATISTICS.	1011 (1010-1111				
tele.	1000	611010	13(4 = 30)	Listin Co	2700774-2010	41207122110	000000000000000000000000000000000000000	1425 1210 12 010				
cute music andial infanction	04.010	04.0010			0000101010	01211-0-02010-0	STATE STATE					
lem de	-	all fail an ID	101110	14/74-420	121.011.020	202000000000	417 (1 A A A A A A A A A A A A A A A A A A	1146 1010 11 11 11				
enae Asia			16/4 10 220	5751004-7474	461/105 10 1255	452/21416-10040	024/2001/02009	10410100410				
han unin thromhosic	-11-12-0	1110010	1000125	17210010740		00001401770	104010101010	1314 035 0 043				
iero de	11 (2 10 10 10 10	12.0214-070	12010611-1001	204 (117 14 202)	100/150 10 1010	492/05214 19200	105 (1601-2672)	1006-0000-0-0500				
fala	14 (4 + 17)	24/4 10 220	00/20 = 220	222.021-226	100/101 + 1020	405 (250 to 1023)	575 GEO 10 1045	1000 000 00000				
la em emb este atra ha	140.00	140030	001002200	272.6317.676		0002001000	63102241027202	1949 11 18 19 39 18				
administration of the second	2/14/38	5014-10	13/410-575	36Dia 530	22/15 (+ 395)	201200-0222	2003061022000	412 105 10 10840				
tala	0.0 + 12	0/21/210	10/0 - 20	54 (10) 173	11020200	124 (27 (2) 22 / 7	247 (2215 1768)	412 85 85 1992				
narc	802 (D %)	0.51524	190.0010	51(10102000	113(2510 582)	118 99 00 6500	312173101340	306 866 10 296 0				
comonary emporism	1010-20	2014-22	20/01 - 12/0	81 (31 to 300)	101/00/07/07	212/2214 (11)	202022-0020	4770144-1104				
ennare fela	1010 30	201018	2017/001240	00 00 00 0000	123130 10470	20100000000	338113310351	1001034101184				
narc	161020	2010012	200.000	80020103180	171(2910497)	230 00 00 0030	3491119101030	3961124101277				
Appendicitis	20/03/01/010	1111111111111	101000-000	05 (40 + 470)	((01)-10)	(2020-012	1211211120	20.000				
emae	32(12(0)84)	15415515430	13415915250	85 (42151725	6612810156	53 (2016 1439	40(13/6)/1240	35 0 2 16 989				
nare	38(1)(0)(0)	194(101653)20	140131352561	66 (49 to 159)	650216130	57 (23 10 144)	47(1535152)	40 (14 00 14.0				
HI & DaleA												
emare	15 (9 to 27)	25(12 to 51)	44 (23 to 84)	61 C 6 to 1400	76 G1 to 1849	86 (29 to 256)	101 G1 to 3300	92 (31 to 2740				
Asie	15 (10 to 240	21 (13 to 34)	43 (29 to 60	68 G7 to 1250	86(43 to 172)	94 (35 to 252)	92 (29 to 291)	100/04 to 2920				
Anaphylaxis												
emare	49116 to 150	50(16 to 154)	39 (16 to 95)	34(13 to 91)	35 (14 to 85)	29 (11 to 76)	23 (7 % 73)	12 (4 to 36)				
Aale	74 (26 to 209)	56(18 to 175)	29 (14 to 63)	24(11 to 53)	25(11 to 53)	24 () to 681	18 (7 to 49)	10 12 to 500				
mmune thrombocytopenia												
emale	12 (8 to 19)	9 (4 10 21)	14 06 to 360	15 (S to 43)	18 (6 to 53)	25 (8 to 82)	30 (8 to 110)	36 (11 to 118)				
Aale	17(12 to 23)	8(31:19)	8121023	10 (3 to 35)	1965 to 578	30 (9 to 105)	41(10 to 170)	56 (15 to 210)				
Ayocarditis or pericarditis												
emale	6 (1 to 25)	7 (2 to 21)	16 (8 to 32)	22 (9 to 53)	31 (13 to 72)	35 (12 to 97)	39(11 to 138)	34 (8 to 143)				
Aale	7 (1 to 32)	1165 to 240	37(16 to 88)	37 (16 to 87)	45 (20 to 102)	491710139	54(15 to 192)	41 (9 to 193)				
Disseminated intravascular	coagulation											
emale	2(<1 to 1040	2(+1 to 48)	4(<1 to 99)	5 (+1 to 75)	10 (1 to 89	14(210.97)	191410.940	16 (3 to 82)				
Aale	3 (<1 to 137)	2(<1 to 40	4(<1 to 31)	511 to 560	12 (1 to 120)	17(2 to 154)	23(4 to 152)	24 (5 to 126)				
Encephalomyelitis												
emale	5 (2 to 15)	512 to 16	512 to 19	611 to 440	9(1 to 61)	11(2 to 62)	12(21077)	14 (2 to 100)				
Aale	5 (2 to 12)	50210140	5 (2 to 17)	7 (1 to 55)	12(3 to 58	16 (3 to 73)	18 (3 to 101)	16(1 to 1800				
larcolepsy												
emale	1(<1 to S)	7(31:17)	15 (4 to S2)	11 (2 to 55)	9(23) 42)	101210-461	8 (1 to 49)	912 to 425				
Aale	1(+1 to 5)	602 to 18	13 (4 to 40)	10(2 to 47)	11 Cl to 44	101210508	10(2 to 68)	10 (2 to 60)				
Suillain-Barré syndrome			_									
female	1 (+1 to 8)	1(+115-2)	3 (1 to 5)	3 (1 60 11)	5 (1 to 18)	6 (2 to 19)	6 (3 to 16)	7 (2 to 22)				
Aale	21<1 to 180	10(10)3	2(1 to 4)	4(2107)	7(410140	8 (3 to 25)	11 (3 to 40)	12 (2 to 680				
ransverse myelitis												
female	1 (+1 to 3)	1(+1tp3)	3(1 to 8)	411 to 12)	4 (2 to 13)	4 (2 to 13)	4(1 to 11)	2 (1 to 9)				
Aale	1(<1 to 2)	10(16)3	2(1 to 6)	311 to 108	4(1 to 10)	4 (1 to 11)	4(1to13)	40 to 10				
Council of International Organizations of Medical Sciences fraguency classification												



#JoinTheJourney





What should we accomplish together in 2022?



Respond at PollEv.com/patrickryan800

What should we accomplish together in 2022?

Тор

Develop a system to generate evidence that characterizes disease and treatment utilization, estimates the effects of medical interventions, and predicts outcom...



The journey to real-world evidence



Current status quo in observational research makes it challenging to build trust in evidence

Does the study provide an unbiased effect estimate? Are the findings generalizable to the population of interest?



Does the analysis actually do what the protocol said it would do?

Engineering open science systems that build trust into the real-world evidence generation and dissemination process



Measurable operating characteristics of system performance





Settings

Tweet

←

Ken Mandl @mandl

Epidemiology is going to need to get closer to actual real time. This just-published JAMA piece measuring the false positive rates of SARS-CoV-2 rapid antigen tests, presents compelling recent data and results, but about the delta variant.



jamanetwork.com

False-Positive Results in Rapid Antigen Tests for SARS-CoV... This study examines the incidence of false-positive results in a sample of rapid antigen tests used to serially screen ...

6:01 AM · Jan 9, 2022 · Twitter Web App



How should we accomplish together in 2022?

COLLABORATIVE ACTIVITIES

COLLABORATIVE ACTIVITIES

OHDSI Working Groups

OHDSI's central mission is to improve health by empowering a community to collaboratively generate the evidence that promotes better health decisions and better care. We work towards that goal in the areas of data standards, methodological research, open-source analytics development, and clinical applications.

Our 27 Working Groups present opportunities for all community members to find a home for their talents and passions, and make meaningful contributions. We are always looking for new collaborators.

See an area where you want to contribute? Please Join The Journey!



Our workgroups hold meetings, share files, chat asynchronously and more in the OHDSI Microsoft Teams environment. Collaborators can request access to any workgroup through an online form available on both OHDSI.org and our main OHDSI Microsoft Teams environment.



An OHDSI regional chapter represents a group of OHDSI collaborators located in a geographic area who wish to hold local networking events and meetings to address problems specific to their geographic location.





Workgroup ground rules

In order to continue progress towards our global mission, we recommend each OHDSI workgroup be responsible for adhering to the following set of community policies.

- Workgroups are teams created to collaborate on addressing scientific problems necessary to advance OHDSI's mission. OHDSI creates a virtual workspace to facilitate workgroup activities, including synchronous meetings and asynchronous chats and fileshares through OHDSI's MSTeams environment.
- Workgroups must create an approved Objectives and Key Results document that states each workgroup's goals and markers of progress. This document should be kept within the "Files" tab of each WG's MS Teams tenant, and it should be referred to in a workgroup meeting at least once per quarter. Approval would be handled by a member of the OHDSI Steering Group.
- Workgroups must maintain updated folders within the MS Teams tenant that contain both meeting agendas and meeting recordings.
- Workgroups should be represented in at least two of the four quarterly workgroup summit that will be scheduled for 2022. Workgroup leads would be ideal representatives, but an active participant can take their place if necessary. All workgroups should do their best to have representation at the initial workgroup summit.
- Workgroups are required to provide one update on an OHDSI community call. This presentation will be recorded, shared on social media, and placed on the new workgroups reference page on OHDSI.org.
- Workgroups should create (or refine if it already exists on the Wiki) one slide that highlights the workgroup objective/mission that will be used on the OHDSI workgroup page. This slide can incorporate text, graphics, references, etc. But it should be a single slide and available by the first workgroup retreat. This slide should be reviewed annually.

https://ohdsi.org/ohdsi-workgroups/



An organizing framework

- Objective: Ambitious goal of what is to be achieved
- Key Result: Specific measurable to benchmark and monitor how we get to the objective





Writing effective OKRs

- Objectives are the 'Whats'. They:
 - Express goals and intents
 - Are aggressive yet realistic
 - Must be tangible, objective, and unambiguous; should be obvious to a rational observer whether an objective as been achieved
 - The successful achievement of an objective must provide clear value to the organization
- Key results are the 'Hows'. They:
 - Express measureable milestones which, if achieved, will advance objective(s) in a useful manner to their constituents
 - Must describe **outcomes**, not activities
 - Must include evidence of completion. This evidence must be available, credible and easily discoverable.



Proposed OKR for OHDSI Steering Workgroup

- Objective: enable the community to collaboratively generate evidence and the scientific work products necessary to generate evidence
- Q1 Key results:
 - 1. 100% of active workgroups have defined OKRs to transparently communicate activities and encourage contributions
 - 2. Convene one OHDSI Workgroup Leader Summit to ensure appropriate communicate across collaborative activities
 - 3. Release a OHDSI community dashboard to allow for regular monitoring the health and progress of our community



OHDSI Authorship requirements

- OHDSI follows the ICMJE guidelines for authorship requirements:
 - Substantial contributions to:
 - the conception or design of the work, OR
 - the acquisition of, or access to the data, OR
 - analysis of the data, OR
 - interpretation of results
 - AND
 - Drafting the work or reviewing it critically for important intellectual content
 - AND
 - Final approval of the version to be published
 - AND
 - Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
- Lead / senior author
 - The contributor who did most of the work is the lead / senior author and can choose to be either the first or the last author



OHDSI publication ground rules

- Before initiating the paper
 - Make sure authors are aware of OHDSI's authorship requirements
- While writing the paper
 - Authors can self-identify as authors when they believe they meet the criteria by
 - adding their name to the manuscript, and
 - writing a short text (one or two sentences) how they meet the 1st criterium (Substantial contribution to the conception or design of the study, the acquisition of or access to the data, analysis of the data, and interpretation of results).
 - For this purpose, a table can be added to the start of the manuscript.
- When submitting
 - The lead / senior author has final authority to decide on whether authors meet the criteria, and may remove authors after communicating with them. The lead / senior author also decides the author order.
 - We encourage publication that are open access. Lead / senior author is responsible for expenses associated with publication decision.

https://www.ohdsi.org/wp-content/uploads/2021/07/OHDSI-Authorship-Guidance.pdf



OHDSI 2022 Schedule of events

				JA	NU/	ARY	F	her	noty	pe	FEI	BRU	ARY					1	MAR	CH						AF	RIL
Su	Mo	Tu	We	Th	Fr	Sa	Su	Mo	Τu	We	Th	Fr	Sa	Su	Mo	Τu	We	Th	Fr	Sa	Su	Mo	Τu	We	Th	Fr	Sa
26	27	28	29		31	1		31	1	2	3	ACMI	- AZ	27	28	1	2	3	4	5	27	28	29		31	1	2
2	3	4	5	6	7	8	6	7	8	9	10	11	12	HLTH	VIVE	FLS	9	10	11	12	3	4	5	6	7	8	9
9	10	11	12	13	14	15	13	14	15	16	17	18	19	13	14	15	IMSS	- FL7	18	19	10	SPE - F	L12	13	14	15	16
16	17	18			21	22	20	21	22	23	24	25	26	20	21	22	23		CIC - 1	x 26	17	18	19	20	21	22	23
23	24	25	2ÉT	HON	28	29	27	28	1	2		-4	5	27	28	29	30	31	1	2	24	25	26	27	28	29	30
30	31	1	2	3	4		6	7		9	10	11	12		4	5	б			9	1	2	3	4	5	б	
					N	AY						JI	UNE						J	ULY					A	UG	UST
Su	Mo	Τu	We	Th	Fr	Sa	Su	Mo	Τu	We	Th	Fr	Sa	Su	Mo	Tu	We	Th	Fr	Sa	Su	Mo	Τu	We	Th	Fr	Sa
1	2	3	4	5	6	7	29		31	1	2	3	4	26	27	28	29		1	2	31	1	A	CC - D	c 4	ML4I N	HC -
8	9	10	11	12	13	14	5	6	7	8	9	10	11	3	4	5	6	7	8	9	7	81	SM - I	DCLO	11	12	13
115	POR -	MD	18	19	20	21	12	13	14	15	16	17	18	10	11	12	13	14	15	16	14	15	16	17	18	19	20
22	23	24	25	26	MIE	– Nice	DIA	- Chic	ago useF	R! - TN	23	OHE	DSI EU-	17	18	19	20	21	22	23	21	22	23	ISPE	-Cope	nhage	en, DK
MIE	– Nice	31	- 1	2		-4	26	27	28	29	30	1	2	24	25	26	27	28	29	30	28	29	30	31	1	SC - S	pain
5				9	10	11	3	4	5	6	7		9	31	1	2		4	5		4	5		7		9	10
				SEPT	ſEM	BER					0	сто	BER					NON	/EM	BER					DEC	EMI	BER
Su	Mo	Τu	We	Th	Fr	Sa	Su	Mo	Tu	We	Th	Fr	Sa	Su	Mo	Tu	We	Th	Fr	Sa	Su	Mo	Tu	We	Th	Fr	Sa
28	29		31	1	2	3	25	26	27	28	29		1	AH	A . II	1	2	3	4	5	27	28	29		1	2	3
4	5	6	7	8	9	10	2	3	4	5	6	7	8	6	AMI	A - DO	c 9	10	11	12	4	5	6	7	8	9	10
11	12	13	14	15	16	17	9	10	11	12	13	14	15	13	14	15	16	17	18	19	11	12	13	14	15	16	17
18	19	20	21	22	23	24	16	17	18	19	20	21	22	20	21	22	23	24	25	26	18	19	20	21	22	23	24
25	26	27	28	29	30	1	23	24	25	26	27	28	29	27	28	29	30	1	2	3	25	26	27	28	29	30	31
2	3	-4			7		30	31	1	2		- 4	5	- 4	5		7			10	1	2	3	-4	5	6	



Conference deadlines

- 31Jan2022 userR call for tutorials
- 1Feb2022 JSM abstract
- 13Feb2022 ISPE abstracts
- 15Feb2022 userR call for abstracts
- 14Apr2022 ML4HC abstracts



Phenotype Phebruary

February 2022: Every day, a new phenotype will be developed and evaluated following OHDSI best practices

Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28						

Daily Task: Given a phenotype target, create a clinical description, review prior work, develop a cohort definition(s) using OHDSI tools (like PHOEBE, ATLAS, APHRODITE), evaluate using OHDSI tools (like CohortDiagnostics, PheValuator), write a summary of findings



Respond at PollEv.com/patrickryan800

What should we accomplish together in 2022?

Тор

Develop a system to generate evidence that characterizes disease and treatment utilization, estimates the effects of medical interventions, and predicts outcom...